Specifically, the upregulation of the pro-apoptotic variant BCL-XS was observed in METTL3-silenced cells, while the anti-apoptotic variant BCL-XL showed increased expression in control glioblastoma cells [43]. The gene discussed is BCL2L1; the disease is glioblastoma.